Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Phase 1, Randomized, Double-blind, Double-dummy, Placebo-controlled, 5-period, Crossover Study Assessing the Effects of Rapastinel Compared to Alprazolam, Ketamine, and Placebo on Simulated Driving Performance in Normal Healthy Participants

To see complete record on, please visit this link

Id: NCT03814733

Organisation Name: Naurex, Inc, an affiliate of Allergan plc

Overal Status: Completed

Start Date: November 5, 2018

Last Update: July 11, 2019

Lead Sponsor: Naurex, Inc, an affiliate of Allergan plc

Brief Summary: Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.

  • Driving Performance

Total execution time in seconds: 0.3216290473938